Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precigen

4.00
+0.510014.61%
Post-market: 3.96-0.0400-1.00%19:57 EDT
Volume:11.97M
Turnover:45.69M
Market Cap:1.41B
PE:-9.31
High:4.05
Open:3.44
Low:3.39
Close:3.49
52wk High:5.23
52wk Low:0.6513
Shares:353.00M
Float Shares:205.00M
Volume Ratio:2.10
T/O Rate:5.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4294
EPS(LYR):-0.4715
ROE:-668.03%
ROA:-67.44%
PB:-38.39
PE(LYR):-8.48

Loading ...

A Look at Precigen (PGEN) Valuation After PAPZIMEOS’ Full FDA Approval and Clinical Breakthroughs

Simply Wall St.
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv

Reuters
·
Oct 14

Sector Update: Health Care Stocks Higher Premarket Monday

MT Newswires Live
·
Oct 13

Precigen Shares Rise on Positive Long-Term Follow-Up Data From Papzimeos

Dow Jones
·
Oct 13

BUZZ-Precigen rises on long-term data of rare respiratory disease therapy

Reuters
·
Oct 13

BRIEF-Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis

Reuters
·
Oct 13

Precigen’s PAPZIMEOS Receives Full FDA Approval as First Therapy for Adults with Recurrent Respiratory Papillomatosis

Reuters
·
Oct 13

Precigen Inc - Surgery Reduction Observed in 95% of Patients by Year 3

THOMSON REUTERS
·
Oct 13

Precigen Inc - 83% of Responders Show Continued Complete Response After 36 Months

THOMSON REUTERS
·
Oct 13

Precigen Inc - No New Safety Events Observed During Long-Term Follow-up

THOMSON REUTERS
·
Oct 13

Precigen Announces Long-Term Follow-up Results Highlighting Ongoing Durable Complete Responses After Treatment With Papzimeos, the First and Only FDA-Approved Therapy for Adults With Recurrent Respiratory Papillomatosis

THOMSON REUTERS
·
Oct 13

Major Stock Sale by Precigen Director Shakes Up Market!

TIPRANKS
·
Oct 02

Director Jeffrey B. Kindler Reports Disposal of Precigen Inc. Common Shares

Reuters
·
Oct 02

Major Moves in Precigen Stock: Insider Trading Revealed!

TIPRANKS
·
Oct 01

Precigen Inc. COO Rutul R. Shah Reports Acquisition of Common Shares

Reuters
·
Oct 01

Phil Tennant, Chief Commercial Officer, Reports Acquisition of Common Shares of Precigen Inc

Reuters
·
Oct 01

CFO Makes Bold Move with Major Precigen Stock Purchase

TIPRANKS
·
Sep 27

Precigen Inc. CFO Harry Thomasian Jr. Reports Acquisition of Common Shares

Reuters
·
Sep 27

Cantor Fitzgerald Sticks to Their Buy Rating for Precigen (PGEN)

TIPRANKS
·
Sep 26

Cencora Inc. to Provide Logistics and Distribution Services for Precigen’s Newly Approved Immunotherapy in the U.S

Reuters
·
Sep 26